Translocator Protein Distribution Volume Predicts Reduction of Symptoms During Open-Label Trial of Celecoxib in Major Depressive Disorder

Overview

Journal Biol Psychiatry

Publisher Elsevier

Specialty Psychiatry

Date 2020 May 14

PMID 32402468

Citations 23

Authors

Sophia Attwells

Elaine Setiawan

Pablo M Rusjan

Cynthia Xu

Celeste Hutton

Dorsa Rafiei

Benjamin Varughese

Alan Kahn

Stephen J Kish

Neil Vasdev

Sylvain Houle

Jeffrey H Meyer

Affiliations

Soon will be listed here.

Abstract

Background: Gliosis is common among neuropsychiatric diseases, but the relationship between gliosis and response to therapeutics targeting effects of gliosis is largely unknown. Translocator protein total distribution volume (TSPO V), measured with positron emission tomography, mainly reflects gliosis in neuropsychiatric disease. Here, the primary objective was to determine whether TSPO V in the prefrontal cortex (PFC) and anterior cingulate cortex (ACC) predicts reduction of depressive symptoms following open-label celecoxib administration in treatment-resistant major depressive disorder.

Methods: A total of 41 subjects with treatment-resistant major depressive disorder underwent one [F]FEPPA positron emission tomography scan to measure PFC and ACC TSPO V. Open-label oral celecoxib (200 mg, twice daily) was administered for 8 weeks. Change in symptoms was measured with the 17-item Hamilton Depression Rating Scale (HDRS).

Results: Cumulative mean change in HDRS scores between 0 and 8 weeks of treatment was plotted against PFC and ACC TSPO V, showing a significant nonlinear relationship. At low TSPO V values, there was no reduction in HDRS scores, but as TSPO V values increased, there was a reduction in HDRS scores that then plateaued. This was modeled with a 4-parameter sigmoidal model in which PFC and ACC TSPO V accounted for 84% and 92% of the variance, respectively.

Conclusions: Celecoxib administration in the presence of gliosis labeled by TSPO V is associated with greater reduction of symptoms. Given the predictiveness of TSPO V on symptom reduction, this personalized medicine approach of matching a marker of gliosis to medication targeting effects of gliosis should be applied in early development of novel therapeutics, in particular for treatment-resistant major depressive disorder.

Citing Articles

Advancing precision psychiatry and targeted treatments: Insights from immunopsychiatry.

Miller A, Berk M, Bloch G, Briquet-Laugier V, Brouillon C, Cuthbert B Brain Behav Immun. 2025; 125:319-329.

PMID: 39828008 PMC: 11903147. DOI: 10.1016/j.bbi.2025.01.002.

Microglial Positron Emission Tomography Imaging In Vivo : Positron Emission Tomography Radioligands: Utility in Research and Clinical Practice.

Ottoy J, De Picker L, Kang M Adv Neurobiol. 2024; 37:579-589.

PMID: 39207714 DOI: 10.1007/978-3-031-55529-9_32.

Neurosteroids and translocator protein 18 kDa (TSPO) ligands as novel treatment options in depression.

Riebel M, Brunner L, Nothdurfter C, Wein S, Schwarzbach J, Liere P Eur Arch Psychiatry Clin Neurosci. 2024; .

PMID: 38976049 DOI: 10.1007/s00406-024-01843-7.

The translocator protein 18kDa ligand etifoxine in the treatment of depressive disorders-a double-blind, randomized, placebo-controlled proof-of-concept study.

Brunner L, Riebel M, Wein S, Koller M, Zeman F, Huppertz G Trials. 2024; 25(1):274.

PMID: 38650030 PMC: 11034134. DOI: 10.1186/s13063-024-08120-x.

P2X7 receptor: a potential target for treating comorbid anxiety and depression.

Liu J, Liu T, Mou L, Zhang Y, Chen X, Wang Q Purinergic Signal. 2024; .

PMID: 38642324 DOI: 10.1007/s11302-024-10007-0.

References

Beck A, Ward C, Mendelson M, Mock J, ERBAUGH J . An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4:561-71. DOI: 10.1001/archpsyc.1961.01710120031004. View

Dupont A, Largeau B, Santiago Ribeiro M, Guilloteau D, Tronel C, Arlicot N . Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases. Int J Mol Sci. 2017; 18(4). PMC: 5412369. DOI: 10.3390/ijms18040785. View

Abbasi S, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S . Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord. 2012; 141(2-3):308-14. DOI: 10.1016/j.jad.2012.03.033. View

Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, Araki E . Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci U S A. 2001; 98(3):1294-9. PMC: 14748. DOI: 10.1073/pnas.98.3.1294. View

Setiawan E, Attwells S, Wilson A, Mizrahi R, Rusjan P, Miler L . Association of translocator protein total distribution volume with duration of untreated major depressive disorder: a cross-sectional study. Lancet Psychiatry. 2018; 5(4):339-347. DOI: 10.1016/S2215-0366(18)30048-8. View

Block M, Zecca L, Hong J . Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2006; 8(1):57-69. DOI: 10.1038/nrn2038. View

Pandey G, Rizavi H, Zhang H, Bhaumik R, Ren X . Abnormal protein and mRNA expression of inflammatory cytokines in the prefrontal cortex of depressed individuals who died by suicide. J Psychiatry Neurosci. 2018; 43(6):376-385. PMC: 6203549. DOI: 10.1503/jpn.170192. View

Chen Q, Luo Y, Kuang S, Yang Y, Tian X, Ma J . Cyclooxygenase-2 Signalling Pathway in the Cortex is Involved in the Pathophysiological Mechanisms in the Rat Model of Depression. Sci Rep. 2017; 7(1):488. PMC: 5428817. DOI: 10.1038/s41598-017-00609-7. View

Trivedi M, Rush A, Wisniewski S, Nierenberg A, Warden D, Ritz L . Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006; 163(1):28-40. DOI: 10.1176/appi.ajp.163.1.28. View

10.

Setiawan E, Wilson A, Mizrahi R, Rusjan P, Miler L, Rajkowska G . Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry. 2015; 72(3):268-75. PMC: 4836849. DOI: 10.1001/jamapsychiatry.2014.2427. View

11.

Owen D, Yeo A, Gunn R, Song K, Wadsworth G, Lewis A . An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2011; 32(1):1-5. PMC: 3323305. DOI: 10.1038/jcbfm.2011.147. View

12.

Ressler K, Mayberg H . Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci. 2007; 10(9):1116-24. PMC: 2444035. DOI: 10.1038/nn1944. View

13.

Betlazar C, Harrison-Brown M, Middleton R, Banati R, Liu G . Cellular Sources and Regional Variations in the Expression of the Neuroinflammatory Marker Translocator Protein (TSPO) in the Normal Brain. Int J Mol Sci. 2018; 19(9). PMC: 6163555. DOI: 10.3390/ijms19092707. View

14.

Wilson A, Garcia A, Parkes J, McCormick P, Stephenson K, Houle S . Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. Nucl Med Biol. 2008; 35(3):305-14. DOI: 10.1016/j.nucmedbio.2007.12.009. View

15.

Holmes S, Hinz R, Conen S, Gregory C, Matthews J, Anton-Rodriguez J . Elevated Translocator Protein in Anterior Cingulate in Major Depression and a Role for Inflammation in Suicidal Thinking: A Positron Emission Tomography Study. Biol Psychiatry. 2017; 83(1):61-69. DOI: 10.1016/j.biopsych.2017.08.005. View

16.

Rojas A, Chen D, Ganesh T, Varvel N, Dingledine R . The COX-2/prostanoid signaling cascades in seizure disorders. Expert Opin Ther Targets. 2018; 23(1):1-13. PMC: 6481174. DOI: 10.1080/14728222.2019.1554056. View

17.

Cosenza-Nashat M, Zhao M, Suh H, Morgan J, Natividad R, Morgello S . Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol. 2008; 35(3):306-28. PMC: 2693902. DOI: 10.1111/j.1365-2990.2008.01006.x. View

18.

Banati R, Myers R, Kreutzberg G . PK ('peripheral benzodiazepine')--binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK11195 binding to activated microglia. J Neurocytol. 1997; 26(2):77-82. DOI: 10.1023/a:1018567510105. View

19.

Holtzheimer P, Husain M, Lisanby S, Taylor S, Whitworth L, McClintock S . Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial. Lancet Psychiatry. 2017; 4(11):839-849. DOI: 10.1016/S2215-0366(17)30371-1. View

20.

Moriguchi S, Wilson A, Miler L, Rusjan P, Vasdev N, Kish S . Monoamine Oxidase B Total Distribution Volume in the Prefrontal Cortex of Major Depressive Disorder: An [11C]SL25.1188 Positron Emission Tomography Study. JAMA Psychiatry. 2019; 76(6):634-641. PMC: 6551845. DOI: 10.1001/jamapsychiatry.2019.0044. View